99
Views
3
CrossRef citations to date
0
Altmetric
Articles

Prediction of therapeutic potency of tacrine derivatives as BuChE inhibitors from quantitative structure–activity relationship modelling

, &
Pages 213-230 | Received 24 Oct 2017, Accepted 01 Jan 2018, Published online: 01 Feb 2018

References

  • H. Boulebd, L. Ismaili, H. Martin, A. Bonet, M. Chioua, J. Marco Contelles, and A. Belfaitah, New (benz) imidazolopyridino tacrines as nonhepatotoxic, cholinesterase inhibitors for Alzheimer disease, Future Med. Chem. 9 (2017), pp. 723–729.
  • I. McDowell, Alzheimer’s disease: Insights from epidemiology, Aging Clin. Exp. Res. 13 (2001), pp. 143–162.
  • T. Arendt, M.K. Brückner, M. Lange, and V. Bigl, Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development: A study of molecular forms, Neurochem. Int. 21 (1992), pp. 381–396.
  • E.K. Perry, R.H. Perry, G. Blessed, and B.E. Tomlinson, Changes in brain cholinesterases in senile dementia of Alzheimer type, Neuropathol. Appl. Neurobiol. 4 (1978), pp. 273–277.
  • A. Enz, R. Amstutz, H. Boddeke, G. Gmelin, and J. Malanowski, Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease, Prog. Brain Res. 98 (1993), pp. 431–438.
  • N.H. Greig, D.K. Lahiri, and K. Sambamurti, Butyrylcholinesterase: An important new target in Alzheimer's disease therapy, Int. Psychogeriatr. 14 (2002), pp. 77–91.
  • P.W. Elsinghorst, C.M. Tanarro, and M. Gütschow, Novel heterobivalent tacrine derivatives as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase, J. Med. Chem. 49 (2006), pp. 7540–7544.
  • S. Hamulakova, L. Janovec, M. Hrabinova, K. Spilovska, J. Korabecny, P. Kristian, K. Kuca, and J. Imrich, Synthesis and biological evaluation of novel tacrine derivatives and tacrine–coumarin hybrids as cholinesterase inhibitors, J. Med. Chem. 57 (2014), pp. 7073–7084.
  • J.L. Marco, C. de los Rı́os, M.C. Carreiras, J.E. Baños, A. Badı́a, and N.M. Vivas, Synthesis and acetylcholinesterase/butyrylcholinesterase inhibition activity of new tacrine-like analogues, Bioorg. Med. Chem. 9 (2001), pp. 727–732.
  • S. Thiratmatrakul, C. Yenjai, P. Waiwut, O. Vajragupta, P. Reubroycharoen, M. Tohda, and C. Boonyarat, Synthesis, biological evaluation and molecular modeling study of novel tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease, Eur. J. Med. Chem. 75 (2014), pp. 21–30.
  • K. Roy, S. Kar, and R.N. Das, Understanding the Basics of QSAR for Applications in Pharmaceutical Sciences and Risk Assessment, Academic Press, San Diego, CA, 2015.
  • S. Simeon, N. Anuwongcharoen, W. Shoombuatong, A.A. Malik, V. Prachayasittikul, J.E.S. Wikberg, and C. Nantasenamat, Probing the origins of human acetylcholinesterase inhibition via QSAR modeling and molecular docking, PeerJ 4 (2016), e2322.
  • K. Roy and P.P. Roy, Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques, Eur. J. Med. Chem. 44 (2009), pp. 2913–2922.
  • N. Akula, L. Lecanu, J. Greeson, and V. Papadopoulos, 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA, Bioorg. Med. Chem. Lett. 16 (2006), pp. 6277–6280.
  • M. Fernández, M.C. Carreiras, J.L. Marco, and J. Caballero, Modeling of acetylcholinesterase inhibition by tacrine analogues using Bayesian-regularized genetic neural networks and ensemble averaging, J. Enzyme Inhib. Med. Chem. 21 (2006), pp. 647–661.
  • M. Saracoglu and F. Kandemirli, The investigation of structure–activity relationships of tacrine analogues: Electronic-topological method, Open Med. Chem. J. 2 (2008), pp. 75–80.
  • M. Jung, J. Tak, Y. Lee, and Y. Jung, Quantitative structure–activity relationship (QSAR) of tacrine derivatives against acetylcholinesterase (AChE) activity using variable selections, Bioorg. Med. Chem. Lett. 17 (2007), pp. 1082–1090.
  • D. Chekmarev, V. Kholodovych, S. Kortagere, W.J. Welsh, and S. Ekins, Predicting inhibitors of acetylcholinesterase by regression and classification machine learning approaches with combinations of molecular descriptors, Pharm. Res. 26 (2009), pp. 2216–2224.
  • K.Y. Wong, A.G. Mercader, L.M. Saavedra, B. Honarparvar, G.P. Romanelli, and P.R. Duchowicz, QSAR analysis on tacrine-related acetylcholinesterase inhibitors, J. Biomed. Sci. 21 (2014), p. 84.
  • M.S. Castilho, R.V.C. Guido, and A.D. Andricopulo, Classical and hologram QSAR studies on a series of tacrine derivatives as butyrylcholinesterase inhibitors, Lett. Drug Des. Discov. 4 (2007), pp. 106–113.
  • J. Fang, R. Yang, L. Gao, D. Zhou, S. Yang, A.L. Liu, and G.H. Du, Predictions of BuChE inhibitors using support vector machine and naive bayesian classification techniques in drug discovery, J. Chem. Inf. Model. 53 (2013), pp. 3009–3020.
  • OECD, Guidance Document on the Validation of (Quantitative) Structure–Activity Relationship [(Q) SAR] Models, Series on Testing and Assessment N° 69, OECD, Paris, 2007.
  • T. Liu, Y. Lin, X. Wen, R.N. Jorissen, and M.K. Gilson, BindingDB: A web-accessible database of experimentally determined protein-ligand binding affinities, Nucleic Acids Res. 35 (2007), D198–D201.
  • G.L. Ellman, K.D. Courtney, V.Jr. Andres, and R.M. Feather-stone, A new and rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharmacol. 7 (1961), pp. 88–95.
  • A.A. Toropov and A.P. Toropova, The index of ideality of correlation: A criterion of predictive potential of QSPR/QSAR models?, Mutat. Res. 819 (2017), pp. 31–37.
  • MOE, Molecular Operating Environment, Chemical Computing Group, Montreal, Canada, 2007.
  • S. Bitam, M. Hamadache, and S. Hanini, QSAR model for prediction of the therapeutic potency of N-benzylpiperidine derivatives as AChE inhibitors, SAR QSAR Environ. Res. 28 (2017), pp. 471–489.
  • D.B. de Oliveira and A.C. Gaudio, BuildQSAR: A new computer program for QSAR analysis, Mol. Inform. 19 (2000), pp. 599–601.
  • G. Snedecor and W. Cochran, Statistical Methods, 6th ed., Oxford and IBH Publishing Co, New Delhi, 1967.
  • C.W. Yap, H. Li, Z.L. Ji, and Y.Z. Chen, Regression methods for developing QSAR and QSPR models to predict compounds of specific pharmacodynamic, pharmacokinetic and toxicological properties, Mini Rev. Med. Chem. 7 (2007), 1097–1107.
  • C.J.C. Burges, A tutorial on support vector machines for pattern recognition, Data Min. Knowl. Discov. 2 (1998), pp. 121–167.
  • V.N. Vapnik and S. Kotz, Estimation of Dependences Based on Empirical Data, Springer Series in Statistics, Springer-Verlag, New York, 1982.
  • J.C.G. Boot, Quadratic Programming: Algorithms, Anomalies, Applications, North-Holland, Amsterdam, 1964.
  • B.E. Boser, I.M. Guyon, and V.N. Vapnik, A training algorithm for optimal margin classifiers, in Proceedings of the Fifth Annual Workshop on Computational Learning Theory, ACM, Pittsburgh, PA, 1992, pp. 144–152.
  • V. Vapnik, The Nature of Statistical Learning Theory, Springer Science & Business Media, 2013.
  • L.V. Fausett, Fundamentals of Neural Networks: Architectures, Algorithms, and Applications, Prentice-Hall, Upper Saddle River, NJ, 1994.
  • R. Wang, J. Jiang, Y. Pan, H. Cao, and Y. Cui, Prediction of impact sensitivity of nitro energetic compounds by neural network based on electrotopological-state indices, J. Hazard Mater. 166 (2009), pp. 155–186.
  • P.K. Ojha, I. Mitra, R.N. Das, and K. Roy, Further exploring rm2 metrics for validation of QSPR models, Chemom. Intell. Lab. 107 (2011), pp. 194–205.
  • L. Eriksson, J. Jaworska, A.P. Worth, M.T. Cronin, R.M. McDowell, and P. Gramatica, Methods for reliability and uncertainty assessment and for applicability evaluations of classification-and regression-based QSARs, Environ. Health Perspect. 111 (2003), pp. 1361–1375.
  • K. Roy, I. Mitra, S. Kar, P.K. Ojha, R.N. Das, and H. Kabir, Comparative studies on some metrics for external validation of QSPR models, J. Chem. Inf. Model. 52 (2012), pp. 396–408.
  • N. Chirico, and P. Gramatica, Real external predictivity of QSAR models: How to evaluate it? Comparison of different validation criteria and proposal of using the concordance correlation coefficient, J. Chem. Inf. Model. 51 (2011), pp. 2320–2335.
  • L.I. Lin, A concordance correlation coefficient to evaluate reproducibility, Biometrics 45 (1989), pp. 255–268.
  • A. Tropsha, P. Gramatica, and V.K. Gombar, The importance of being earnest: Validation is the absolute essential for successful application and interpretation of QSPR models, Mol. Inform. 22 (2003), pp. 69–77.
  • V.K. Agrawal and P.V. Khadikar, QSAR prediction of toxicity of nitrobenzenes, Bioorg. Med. Chem. 9 (2001), pp. 3035–3040.
  • I. Mitra, A. Saha, and K. Roy, Exploring quantitative structure–activity relationship studies of antioxidant phenolic compounds obtained from traditional Chinese medicinal plants, Mol. Simul. 36 (2010), pp. 1067–1079.
  • M. Hamadache, S. Hanini, O. Benkortbi, A. Amrane, L. Khaouane, and C.S. Moussa, Artificial neural network-based equation to predict the toxicity of herbicides on rats, Chemom. Intell. Lab. 154 (2016), pp. 7–15.
  • F. Sahigara, K. Mansouri, D. Ballabio, A. Mauri, V. Consonni, and R. Todeschini, Comparison of different approaches to define the applicability domain of QSAR models, Molecules 17 (2012), pp. 4791–4810.
  • F. Sahigara, D. Ballabio, R. Todeschini, and V. Consonni, Defining a novel k-nearest neighbours approach to assess the applicability domain of a QSAR model for reliable predictions, J. Cheminform. 5 (2013), p. 27.
  • K. Roy, S. Kar, and P. Ambure, On a simple approach for determining applicability domain of QSAR models, Chemom. Intell. Lab. 145 (2015), pp. 22–29.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.